[go: up one dir, main page]

MX2010003179A - Metodos de sintesis para peptidos anti-vih terapeuticos. - Google Patents

Metodos de sintesis para peptidos anti-vih terapeuticos.

Info

Publication number
MX2010003179A
MX2010003179A MX2010003179A MX2010003179A MX2010003179A MX 2010003179 A MX2010003179 A MX 2010003179A MX 2010003179 A MX2010003179 A MX 2010003179A MX 2010003179 A MX2010003179 A MX 2010003179A MX 2010003179 A MX2010003179 A MX 2010003179A
Authority
MX
Mexico
Prior art keywords
synthesis
methods
therapeuthic
hiv peptides
peptides
Prior art date
Application number
MX2010003179A
Other languages
English (en)
Inventor
Paul E Friedrich
Huyi Zhang
Brian L Bray
Barbara E Johnston
Stephen E Schneider
Nicolai A Tvermoes
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of MX2010003179A publication Critical patent/MX2010003179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen m?todos para s?ntesis de p?ptidos. En particular, en la presente se proveen m?todos de s?ntesis para p?ptidos antivirales terap?uticos.
MX2010003179A 2007-09-25 2008-09-25 Metodos de sintesis para peptidos anti-vih terapeuticos. MX2010003179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99531807P 2007-09-25 2007-09-25
PCT/US2008/011147 WO2009042194A2 (en) 2007-09-25 2008-09-25 Methods of synthesis for therapeuthic anti-hiv peptides

Publications (1)

Publication Number Publication Date
MX2010003179A true MX2010003179A (es) 2010-04-30

Family

ID=40092022

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003179A MX2010003179A (es) 2007-09-25 2008-09-25 Metodos de sintesis para peptidos anti-vih terapeuticos.

Country Status (9)

Country Link
US (1) US20100261876A1 (es)
EP (1) EP2201028A2 (es)
JP (1) JP2010540528A (es)
KR (1) KR20100080812A (es)
CN (1) CN101874038A (es)
BR (1) BRPI0817697A2 (es)
CA (1) CA2700354A1 (es)
MX (1) MX2010003179A (es)
WO (1) WO2009042194A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678125A (zh) * 2007-04-03 2010-03-24 特里梅里斯公司 用于递送抗病毒肽治疗剂的新制剂
EP2716650A1 (en) * 2011-05-31 2014-04-09 Ajinomoto Co., Inc. Method for producing peptide
JP6011528B2 (ja) * 2011-05-31 2016-10-19 味の素株式会社 ペプチドの製造方法
US10406098B2 (en) 2015-11-16 2019-09-10 Evonik Roehm Gmbh Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途
CN112851789B (zh) * 2021-02-04 2022-10-18 大理大学 一种脑靶向hiv进入抑制剂多肽及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) * 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) * 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) * 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) * 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1993007603A1 (en) * 1991-10-04 1993-04-15 Cornett Robert H Approaching emergency vehicle warning system
DE69326069T2 (de) * 1992-07-20 2000-03-23 Duke University, Durham Zusammensetzungen die die hiv replikation inhibieren
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE69426292T2 (de) * 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
JPH11507632A (ja) * 1995-06-07 1999-07-06 トリメリス，インコーポレーテッド 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) * 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
CN1173742C (zh) * 1997-12-26 2004-11-03 山之内制药株式会社 缓释药物组合物
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6541020B1 (en) * 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6992065B2 (en) * 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
IL159048A0 (en) * 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
CN1100564C (zh) * 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
BRPI0418304A (pt) * 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
EP1725262B1 (en) * 2004-03-15 2021-05-26 Nektar Therapeutics Polymer-based compositions and conjugates of hiv entry inhibitors
JP4682251B2 (ja) * 2006-02-02 2011-05-11 トリメリス，インコーポレーテッド 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
CN101678125A (zh) * 2007-04-03 2010-03-24 特里梅里斯公司 用于递送抗病毒肽治疗剂的新制剂

Also Published As

Publication number Publication date
JP2010540528A (ja) 2010-12-24
CN101874038A (zh) 2010-10-27
BRPI0817697A2 (pt) 2015-04-07
EP2201028A2 (en) 2010-06-30
CA2700354A1 (en) 2009-04-02
KR20100080812A (ko) 2010-07-12
WO2009042194A2 (en) 2009-04-02
US20100261876A1 (en) 2010-10-14
WO2009042194A3 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
TN2011000172A1 (en) Therapeutic antiviral peptides
IN2012DN06629A (es)
TW200716646A (en) (S)-N-methylnaltrexone
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
MY158257A (en) Forms of rifaximin and uses thereof
TN2014000134A1 (en) Therapeutic peptides
MX2020005214A (es) Formulaciones de anticuerpos.
IN2015DN02577A (es)
MY146112A (en) Long-term feed - cancer patient
MX2010003045A (es) Composiciones de ciclosporina.
IN2012KN02804A (es)
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX384662B (es) Incremento en la biodisponibilidad de farmacos en la terapia con naltrexona
MX2010003179A (es) Metodos de sintesis para peptidos anti-vih terapeuticos.
IL200000A0 (en) Process for the preparation of 2-substituted-5-(1-alkylthio) alkylpyridines
IN2013MN00733A (es)
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
NO20091386L (no) Fenyloksyanilinderivater
MX2009007054A (es) Uso terapeutico novedoso para tratar leucemia.
UA96574C2 (ru) Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции
EP2029615B8 (en) A process for the preparation of an oxaliplatin
GB0818080D0 (en) Immunogenic peptides

Legal Events

Date Code Title Description
FA Abandonment or withdrawal